Maria Veronica Lopez

Title: Maria Veronica Lopez: Innovator in Oncolytic Virus Therapy

Introduction

Maria Veronica Lopez is a prominent inventor based in Buenos Aires, Argentina. She has made significant contributions to the field of immuno-oncology, particularly through her innovative work on oncolytic adenoviral vectors. Her research focuses on developing therapies that harness the power of viruses to target and destroy cancer cells.

Latest Patents

Maria Veronica Lopez holds a patent for an oncolytic adenoviral vector and methods of use. This patent describes a conditionally-replicating serotype 5 adenovirus or adenoviral vector that expresses a mutant E1A protein. This expression is controlled by a promoter responsive to hypoxia and inflammation, along with one or more immune modulators under the control of a tumor-specific promoter. The adenovirus also comprises serotype 3 fiber and hexon proteins. Additionally, the patent outlines a method for inducing cytotoxicity in tumor cells using a composition containing the adenovirus or adenoviral vector.

Career Highlights

Maria Veronica Lopez is associated with Unleash Immuno Oncolytics, Inc., where she continues to advance her research in cancer therapies. Her work has positioned her as a key figure in the development of innovative treatments that leverage the immune system to combat cancer.

Collaborations

She has collaborated with notable researchers in her field, including David T Curiel and Osvaldo Podhajcer. These collaborations have further enriched her research and contributed to the advancement of oncolytic virus therapies.

Conclusion

Maria Veronica Lopez is a trailblazer in the field of immuno-oncology, with her innovative patent on oncolytic adenoviral vectors paving the way for new cancer treatments. Her contributions are vital to the ongoing fight against cancer, showcasing the potential of viral therapies in modern medicine.